TransMedics Group, Inc. (NASDAQ:TMDX) Short Interest Up 30.9% in October

TransMedics Group, Inc. (NASDAQ:TMDX) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 8,430,000 shares, an increase of 30.9% from the October 15th total of 6,440,000 shares. Based on an average daily trading volume, of 1,390,000 shares, the short-interest ratio is presently 6.1 days.

TransMedics Group Trading Down 8.9 %

TransMedics Group stock traded down $7.88 during trading hours on Friday, hitting $80.48. The stock had a trading volume of 2,305,980 shares, compared to its average volume of 969,652. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. TransMedics Group has a one year low of $63.85 and a one year high of $177.37. The stock has a market cap of $2.70 billion, a price-to-earnings ratio of 85.62 and a beta of 2.08. The business’s 50 day simple moving average is $125.63 and its 200-day simple moving average is $139.09.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The business had revenue of $108.76 million for the quarter, compared to the consensus estimate of $115.00 million. During the same quarter last year, the firm posted ($0.12) EPS. The business’s revenue for the quarter was up 63.7% compared to the same quarter last year. On average, equities analysts predict that TransMedics Group will post 1.07 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the sale, the chief executive officer now owns 61,643 shares in the company, valued at $8,180,642.53. This trade represents a 12.27 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Edward M. Basile sold 6,750 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the sale, the director now owns 732 shares of the company’s stock, valued at approximately $61,158.60. This trade represents a 90.22 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 36,958 shares of company stock valued at $5,230,528 over the last quarter. Company insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of TMDX. Vaughan Nelson Investment Management L.P. bought a new position in TransMedics Group during the 2nd quarter valued at approximately $39,862,000. Driehaus Capital Management LLC grew its holdings in shares of TransMedics Group by 15.8% during the second quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock valued at $223,832,000 after buying an additional 202,867 shares during the last quarter. Principal Financial Group Inc. raised its stake in shares of TransMedics Group by 260.1% in the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock worth $31,759,000 after purchasing an additional 146,115 shares during the last quarter. Hood River Capital Management LLC bought a new stake in shares of TransMedics Group in the second quarter worth approximately $18,854,000. Finally, Canada Pension Plan Investment Board purchased a new position in shares of TransMedics Group in the 2nd quarter worth $16,086,000. 99.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

TMDX has been the subject of several recent analyst reports. Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Needham & Company LLC reduced their price target on TransMedics Group from $208.00 to $109.00 and set a “buy” rating for the company in a research report on Tuesday, October 29th. Robert W. Baird lowered their target price on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 29th. Oppenheimer cut their price target on TransMedics Group from $200.00 to $125.00 and set an “outperform” rating for the company in a report on Tuesday, October 29th. Finally, Stephens boosted their price target on TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $144.80.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.